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Summary
Multiple breath inert gas washout (MBW) is a lung function
technique to measure ventilation inhomogeneity. The
technique was developed more than 60 years ago, but not
much used for many decades. Technical improvements,
easy protocols and higher sensitivity compared with stan-
dard lung function tests in some disease groups have led
to a recent renaissance of MBW.
The lung clearance index (LCI) is a common measure
derived from MBW tests, and offers information on lung
pathology complementary to that from conventional lung
function tests such as spirometry. The LCI measures the
overall degree of pulmonary ventilation inhomogeneity.
There are other MBW-derived parameters, which describe
more regional airway ventilation and enable specific infor-
mation on conductive or acinar ventilation inhomogeneity.
How this specific ventilation distribution is exactly related
to different disease processes has not entirely been exam-
ined yet.
MBW measurements are performed during tidal breathing,
making this technique attractive for children, even young
children and infants. These benefits and the additional
physiological information on ventilation inhomogeneity
early in the course of lung diseases have led to increasing
research activities and clinical application of MBW, espe-
cially in paediatric lung diseases such as cystic fibrosis
(CF). In these patients, LCI detects early airway damage
and enables monitoring of disease progression and treat-
ment response. Guidelines for the standardisation of the
MBW technique were recently published. These guide-
lines will, hopefully, increase comparability of LCI data ob-
tained in different centres or intervention trials in children
and adults.
In this non-systematic review article, we provide an
overview of recent developments in MBW, with a special
focus on children. We first explain the physiological and
technical background to this technique with a short expla-
nation of several methodological aspects that are impor-
tant for understanding the principle behind the technique
and enable high quality measurements. We then provide
examples of MBW application in different lung diseases of
children and adults, with regards to both clinical applica-
tion and research activities. Lastly, we report on ongoing
clinical trials using MBW as outcome and give an outlook
on possible future developments.
Key words: lung clearance index, multiple breath
washout, paediatric, pulmonary function tests, ventilation
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Introduction
For decades, conventional spirometry has been the stan-
dard technique to assess the degree of airway obstruction
in most chronic lung diseases, including cystic fibrosis
(CF), asthma, and chronic lung disease of prematurity.
However, there is mounting evidence that, because of its
underlying physiological principle, spirometry is insensi-
tive for the assessment of peripheral airway involvement
and for the assessment of ventilation distribution. This re-
sulted in an increased interest in gas dilution techniques, in
particular multiple breath-washout (MBW), for the assess-
ment of small airway function, i.e. efficient, homogeneous
ventilation distribution [1, 2].
MBW was first described more than 60 years ago by Ward
S. Fowler [3]. In his pioneering work of 1952, he compared
nitrogen clearance from single breath washouts between
healthy subjects and patients with cardiopulmonary dis-
ease, to assess the degree of uneven alveolar gas dilution
[3]. However, the technique was little appreciated until gas
ABBREVIATIONS
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analysers and computers were further developed to im-
prove automated analysis of gas and volume signals dur-
ing measurements [4, 5]. Today, the technique is returning
to “prime time”, especially in the paediatric pulmonology
community. Recently, an international workshop reviewed
current literature on the monitoring of preschool lung dis-
ease. Besides detailed recommendations for technical stan-
dards and measurement procedures, this report suggested
MBW as a promising tool in preschool children with CF,
highlighting its importance [6].
In this non-systematic review article, we provide an
overview of recent developments in MBW. Pubmed and
the North American and European clinical trial registries
were searched. Search terms were: CF, lung clearance in-
dex, lung function test, lung disease, and washout. We
specifically focused on literature in children. We first ex-
plain the physiological and technical background to this
technique with a short explanation of several methodolog-
ical aspects important for understanding the principle be-
hind the technique and enable high quality measurements.
We then provide examples of MBW application in differ-
ent lung diseases of children and adults, with regards to
both clinical application and research activities. Lastly, we
report on ongoing clinical trials using MBW as outcome
and give an outlook on possible future developments.
Physiological background, mechanisms of ven-
tilation inhomogeneity
The main function of the human lung is to homogeneously
ventilate the lungs, enabling efficient gas exchange. Dur-
ing fetal lung development, the lungs grow from proximal
to distal by a continuous division of the airways, which
later form the unique structure of the bronchial tree. The
bronchial tree consists on average of 23 bronchial genera-
tions, but gas exchange only occurs in approximately the
last 9 generations. The bronchial tree resembles a self-sim-
ilar, so-called fractal structure, enabling efficient gas trans-
port. Normal ventilation distribution occurs by convection
and diffusion. Three main mechanisms of ventilation inho-
mogeneity are currently known: (i) convection-dependent
inhomogeneity in the conducting airway zone (more proxi-
mal airways); (ii) diffusion-limitation related inhomogene-
ity in the diffusion-dependent airway zone (distal airways,
acini); (iii) interaction between convection and diffusion in
an intermediate zone at the level of the diffusion-convec-
tion front, which is thought to arise at the acinar entrance
[7]. The acinar compartment, the alveoli, is separated by
a thin tissue layer from a capillary meshwork and forms a
large surface for efficient oxygen and carbon dioxide gas
exchange.
Technical background
MBW testing
Besides analysis devices, MBW tests require only a tight
facemask or mouthpiece and quiet tidal breathing for 2
to 10 minutes per test, making this technique applicable
across all age groups, even infancy. Measurements in in-
fants are made in a supine position during quiet non-rapid-
eye-movement sleep (or with sedation), using a face mask.
In older children and adults, measurements are usually
performed in a sitting position with a mouth-piece and
nose clip. Differences between sitting and supine positions
have been described [8] and need to be taken into account
when comparing data or in longitudinal studies. To support
regular breathing patterns, distraction with videos is rec-
ommended for children [9], and visual breathing pattern
feedback may be useful for adolescents and adults [10].
Because time for triplicate testing can be demanding in
busy outpatient clinics or for patients with advanced lung
disease, promising abbreviated protocols have been pro-
posed [11, 12].
Each MBW test consists of a wash-in and a washout phase.
Depending on the gas for the MBW test employed, there
are in principle two different ways to perform MBW:
1. When an inert extrinsic gas (4% sulphur hexafluoride;
20% helium) is used, the gas mixture is inspired until
an equilibrium is reached; the washout phase (breath-
ing room air) starts from this point of equilibrium.
2. For inert intrinsic gas (nitrogen), no formal wash-in
phase is required for the first of the three tests. For ni-
trogen washout of the airways, 100% oxygen is usual-
ly used.
Regardless of the gas used, the washout is stopped when
the test gas reaches 1/40th (or 2.5% from the initial starting
concentration set to 100%) of the initial gas concentration
[7]. This cut-off was recently challenged, in order to im-
prove comparability between different techniques, as the
role of nitrogen is not fully understood yet [13]. The typ-
ical equipment setup for sulphur hexafluoride MBW is
shown in figure 1.
MBW outcomes
Three main parameters are reported from MBW tests: the
functional residual capacity (FRC), the lung clearance in-
dex (LCI) and moment ratios (MR). The FRC is the vol-
ume of air present in the lungs after tidal expiration in ven-
tilated regions of the lungs; LCI and MR are both measures
of global ventilation inhomogeneity. Besides LCI and MR,
other parameters specifically assessing peripheral airway
ventilation can be calculated, as detailed below.
Given that MBW setups measure inert gas concentrations
and the cumulative volume required to washout the resting
Figure 1: Schematic illustration of a sulphur hexafluoride (SF6)
multiple breath inert gas washout test. Equipment displayed in-
cludes a facemask, flowmeter, gas analyser and the inert extrinsic
gas used. The wash-in phase of 4% SF6 is given in panel A, the
washout phase in panel B. The red tracing in panel C shows the
decay in the SF6 concentration during the washout-phase.
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lung volume (FRC), the latter can be calculated. The FRC
is derived from a ratio: the cumulative expired volume
(CEV) of the inert gas over the difference between the end-
tidal concentrations of the inert gas (Cet) measured at the
start (Cetstart) and end (Cetend) of the washout. The LCI is
a volume ratio, net CEV (including all gas fractions) over
FRC: LCI = CEV/FRC. An increased ventilation inhomo-
geneity would thus result in more tidal breaths (greater net
CEV) needed to wash out the inert gas, and in an increased
LCI. To adjust for lung size, net CEV is divided by FRC to
obtain LCI.
MR also quantify ventilation inhomogeneity, but are less
commonly used. They have been described in detail else-
where [4, 14–23]. The advantage of MR over LCI is that
they can be weighted to specific parts of the washout
curve.
Specific markers for peripheral lung ventilation are the
slopes of alveolar phase III (SIII) of the inert gas ex-
pirogram. The first SIII value is thought to reflect venti-
lation inhomogeneity within diffusion-convection-depen-
dent acinar airways (Sacin), whereas the subsequent evolu-
tion of SIII values from lung turnover 1.5 to 6.0 is thought
to reflect ventilation inhomogeneity within convection-de-
pendent conducting airways (Scond) [7, 24]. Although
these indices were derived from numerical lung models
[24], recent comparative data from ventilation imaging
techniques are reassuring [25, 26].
MBW equipment and analysis procedures
One of the earliest and most recognised systems for MBW
is based on a respiratory mass spectrometer, which allows
simultaneous measurement of multiple gases at 33 Hz or
higher. Drawbacks of the AMIS 2000 (Innovision, Den-
mark) relate to the custom design, sophisticated mainte-
nance and costs [27]. Other customised systems have been
described in detail elsewhere [7, 28]. Currently, there are at
least three commercially available devices, which strong-
ly differ in regard to the inert gas used, the gas analyser,
analysis algorithms and the age group for which applica-
tion is recommended (table 1).
Gases for MBW testing
Depending on the choice of gas and setup, derived MBW
indices differ substantially [54]. For example, helium is
much lighter than sulphur hexafluoride and generates sys-
tematically higher LCI values [7]. Furthermore, in subjects
with emphysematous diseases, the diffusion equilibrium in
the enlarged peripheral airways differs between gases. Oth-
er aspects regarding the use of sulphur hexafluoride are its
costs and limited availability, since it belongs to the most
potent greenhouse gases. Applications using lower sulphur
hexafluoride fractions may be more suitable for routine
use.
The choice of intrinsic gas (nitrogen) for MBW has the
advantage that the oxygen required for washout is widely
available and affordable. Another strength is that nitrogen
is present in all parts of the lung and this gas, therefore,
has great sensitivity to detect abnormality compared with
extrinsic gases. Further, the wash-in is with room air and
without the need for a tight mouthpiece, making it much
easier to apply.
There is clear evidence that breathing patterns may change
during MBW. Although in adults fixed 1-L breathing pro-
tocols may have some advantages with regards to slope
III standardisation and analysis [67], most studies nowa-
days use free tidal breathing in order to take advantage of
the natural breathing pattern. This is especially important
in children, as fixed breathing protocols have been shown
to influence MBW outcome parameters substantially [68].
Application of 100% oxygen in MBW was shown to alter
breathing patterns in infants [22], and sulphur hexafluoride
induced transient hypopnoea in preterm and healthy infants
[69, 70]. However, in school-age children, MBW indices
were not influenced by inhalation of 100% oxygen [71].
The effect of nitrogen back-diffusion from tissue nitrogen
also requires further studies.
Table 1: Currently available multiple breath washout devices.
Eco Medics infants Eco Medics preschool and
older
ndd EasyOne Pro LAB* Innovision Innocor
Method SF6 N2 N2 SF6
Flow/volume measurement Ultrasonic flowmeter; Ultrasonic flowmeter Ultrasonic flowmeter Pneumotachometer
Tracer gas measurement indirect via molar mass mainstream Indirect via O2 and CO2 mea-
surement
Indirect via molar mass, O2
and CO2 measurement
Direct via photoacoustic spectroscopy,
gas reservoir bag
Gas concentration 4% SF6 100% O2 100% O2 SF6 mixture: 0.1% or 0.2% SF6 (27.6%
O2, 0.35% N2O)
Validation studies Lung model Schmidt [29], Gustafs-
son [30]
Lung model and in vivo Singer
[31]
- In vivo Horsley [10] Lung model
and in vivo Gonem [32]
Methodological studies Anagnostopoulou [33], Latzin [34] Jensen [35], Summermatter
[36]
- Horsley [37], Downing [38], Grønbæk
[39], Gonem [25], Gonem [32], Nielsen
[40], Shawcross [41]
Application in healthy Fuchs [42], Anagnostopoulou [33],
Gray [43] Gray [44]
Downing [38]
Studies in cystic fibrosis Belessis [45], Simpson [46], Hall
[47]
Stanojevic [48], Stahl [49],
Amin [50], Ramsey [51]
Davies [52]
Cystic fibrosis and controls Singer [53], Poncin [54] Poncin [54] Downing [38]
Other disease groups Hulskamp [55], Latzin [56] Yammine [57], Boon [58], Nyi-
las [59], Madsen [60], Jaren-
back [61]
Fuchs [62] Macleod [63]
CO2 = carbon dioxide; O2 = oxygen; N2 = nitrogen; N2O = nitrogen dioxide; SF6 = sulphur hexafluoride This table is meant to provide a current overview of available setups
and does not necessarily represent the full body of existing literature. Please refer to the respective manufacturer for an update on current studies and recent developments.
Manufacture of AMIS 2000 (Innovision) has been discontinued (http://www.innovision.dk/Products/AMIS_2000.aspx, accessed on 1 March 2017). * Before 2012, ndd EasyOne
Pro was in use for multiple-breath washout measurement using 4% SF6 (MM sidestream) (Fuchs [64], Fuchs [65], Ellemunter [66], Fuchs [62]).
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Sample flow and gas analysis
Tidal flow and gases are usually measured within the main
path of the respiratory flow (mainstream), or a continuous
sample is taken from a capillary (sidestream). Sidestream
sample flow (suction) may alter the analyser response and
add noise to “small” signals from infants. Flows and in-
tegrated volumes have to be further corrected for BTPS
(body temperature, pressure, saturated with water) [7]. The
gas concentrations can then be measured directly (respira-
tory mass spectrometry, infrared, etc.) or indirectly (molar
mass, cumulative gas fractions, etc.) [31]. Of note, usually
the flow and gas signals are not sampled at the same sensor
point. Signals, therefore, need to be aligned in time. Poor
BTPS correction or signal misalignment can be a source of
error in MBW outcomes [7, 36].
Impact of dead space on LCI
Dead space roughly consists of two compartments. Tech-
nical dead space consists of the volume of MBW hardware
(mask, mouthpiece, and tubes) required to transport gases
to the sensors. Anatomical and physiological dead spaces
are the volume of upper and lower airways, respectively,
which transport gases but do not participate in gas ex-
change. Technical dead space is hardware specific and af-
fects LCI [35, 72]. The impact seems larger in younger
children than in adults, and is apparently independent of
lung disease. Thus, a small technical dead space of ≤2 ml/
kg is recommended [73].
Software for MBW analysis
For analyses of MBW indices, commercial online and of-
fline software is available, and several custom-made soft-
ware applications exist. Offline data analysis was frequent-
ly used in the past, but it has the disadvantage that analysis
is time consuming, and this limits its application in clinical
settings. Several studies reported an effect on MBW in-
dices of different software and settings [33, 36, 74]. Cur-
rent commercial setups usually provide recording and
analysis software on board. These applications undergo
constant development and software updates need to be val-
idated in clinical settings for reliability [75–77].
Normative data for MBW
Depending on the age of subjects and the factors men-
tioned above (gas, equipment, dead space, software), LCI
is usually below 8.5 lung turnovers (LCI units) in healthy
subjects. However, normative data for MBW measure-
ments across different age groups are scanty [42]. Some
data stem from customised setups [78], which limits their
generalisability. Furthermore, data are not only system, but
also gas, specific and may even be influenced by the analy-
sis approach. The latter has been shown for both healthy
individuals and patients with CF [33, 74]. Two studies re-
ported MBW reference values for infants, recorded with
common available equipment from a large Swiss [42] and
African population [43] and with measurements conduct-
ed at 5 weeks postmenstrual age. Since LCI is thought to
decrease throughout infancy and early childhood, then re-
main constant and increase in the elderly [78], these ref-
erence data cannot be applied to other age groups. There
are other relevant factors that influence MBW measures,
including the posture during tests (supine or seated) [8],
the gas choice (sulphur hexafluoride, nitrogen) [35], dead
space [34, 72, 79], as well as sedation, which may play a
significant role in LCI variation with age.
Limitations of MBW testing, knowledge gaps
Limitations to MBW application relate to technical and
physiological aspects. Much effort has been made to im-
prove standardisation of MBW protocols and analyses, but
there are still several unanswered questions, as mentioned
above. Overcoming these knowledge gaps seems difficult,
considering the, at times, poor software transparency [76].
Besides software, there are other aspects that may change
MBW indices. There is evidence that interventions prior
to MBW testing, such as raised volume rapid thoracoab-
dominal compression [80] or physiotherapy [81–83], sub-
sequently effect MBW outcomes. Other important aspects
have been outlined previously [7].
The impact of repeat LCI measurements on respiratory dis-
ease outcomes is largely unknown. Data suggest a clear as-
sociation with infection burden, structural airway pathol-
ogy or later pulmonary exacerbation in CF, although it
remains unclear what change in LCI should prompt clini-
cians to intervene. As for most lung function outcome pa-
rameters, the beneficial effect of regular measurement of
LCI in clinics on disease outcome has not been assessed
yet. Recent data may help to establish what would con-
stitute a clinically important change in LCI, at least in
preschool children [48].
Single breath washout
There are techniques other than MBW to assess ventilation
inhomogeneity: single breath washout tests, with a single
or double inert tracer gas mixture. Several studies have
used this technique, also in younger children. Single breath
washout has been used in CF patients to detect early lung
disease [84], assess response to airway clearance [85], and
to study the involvement of small airways in patients with
mild asthma [86], COPD [87–90], PCD [60, 91] and bron-
chiolitis obliterans as a complication after lung transplan-
tation [92–94]. SBW may be attractive for clinical settings,
since measurements can be completed more quickly than
for MBW, and single breath washout can be used during
normal tidal breathing or forced manoeuvres. Although ac-
ceptable reproducibility of this test has been reported in
adults [89] and children [84], reproducibility is lower than
with MBW. Several unanswered technical aspects also re-
main (i.e., impact of breathing pattern) [7, 95, 96], preclud-
ing its use for clinical decision making.
Application of MBW in lung diseases
Cystic fibrosis
CF is an inherited life-limiting disease with a mean preva-
lence of approximately 0.8/10 000 in Europe and the Unit-
ed States [97]. In Switzerland, newborn screening, intro-
duced in 2011, enables early CF diagnosis and follow-up
of lung function [77]. CF lung disease is characterised by
mucus plugging, chronic infection and inflammation re-
sulting in irreversible lung damage. Treatment advances
have resulted in the preservation of normal forced expira-
tory volume in one second (FEV1) (>˗1.64 z-scores) into
young adulthood, but progression of bronchiectasis may be
undetected by spirometry [98]. This led to more research
into detection of early airway abnormalities in CF patients
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with MBW, and several observational studies and clinical
trials support its usefulness.
Observational studies
The majority of longitudinal data from infants and children
with CF are currently obtained from two large prospective
cohorts, the Australian Respiratory Early Surveillance
Team for Cystic Fibrosis (AREST-CF) and the London
Cystic Fibrosis Collaboration (LCFC), (reviewed in [99]).
There is mounting evidence that, compared with healthy
controls, LCI is already abnormal shortly after birth in pa-
tients with CF [1, 100, 101]. In infancy, LCI is normal
in approximately half of the infants. Interestingly, there
are infants with normal LCI values in the presence of ab-
normal forced volume values (as assessed with the raised
volume rapid thoracoabdominal compression technique)
[102]. Several observational studies “tracked” LCI from
preschool to school age [103, 104]. A multicentre study as-
sessed LCI at several time points and was able to identify
significant deterioration of LCI in CF over time, which was
not detected by spirometry [48]. Another study found that
LCI during preschool years was more likely to be abnor-
mal than spirometry, and an abnormal LCI in preschool
children predicted both abnormal LCI, and abnormal
spirometry at school age [103].
Studies in infants [45], children [53, 102] and adults [105]
showed that patients with evidence of a bacterial infection
were more likely to have abnormal LCI values. Findings
from the longitudinal study AREST-CF suggested that LCI
has a more pronounced increase in infants with airway
infections compared with those without, and that this in-
crease was long lasting [46]. Several studies used MBW to
monitor treatment response to antibiotic therapy in infants
and adult patients with CF [49, 106, 107]. A systematic re-
view included data from 176 exacerbations and observed
an overall decrease, albeit small (≈˗3%), in LCI after an-
tibiotic treatment. The LCI response to therapy was very
heterogeneous in CF patients, and is not fully understood
[106].
Clinical trials
There is an ongoing debate about whether or not MBW can
be used in multicentre trials. The Cystic Fibrosis Founda-
tion Workshop Report from 2015, for example, concluded
that lack of knowledge on MBW equipment hampers rou-
tine application of MBW in clinical trials [6]. On the oth-
er hand, the European CF Society Clinical Trial Network
Standardization Committee [108] suggested LCI as an out-
come measure, especially in young children and those with
mild CF disease.
To date, several single- and multicentre trials in CF pa-
tients that used LCI as outcome have been published. Two
multicentre interventional studies investigated the treat-
ment effect of drugs modifying the cystic fibrosis trans-
membrane conductance regulator (CFTR) defect in CF pa-
tients. One study enrolled patients aged >6 years, with at
least one copy of the rare G551D mutation and normal
FEV1, and assessed the ability of LCI to detect a treatment
effect of ivacaftor. Treatment with ivacaftor resulted in sig-
nificant improvement of LCI compared with placebo [52].
Another study enrolled patients aged 6 to 11 years and ho-
mozygous for F508del-CFTR, to assess the treatment ef-
fect of combined therapy with ivacaftor and lumacaftor on
LCI. No changes in FEV1 were observed after 24 weeks of
intervention, whereas there was significant improvement
in LCI [109].
Two trials examined the usefulness of LCI in infants and
preschool children to assess treatment response to hyper-
tonic saline inhalation [50, 110]. In one study, MBW mea-
surements were made before and after treatment with hy-
pertonic saline (twice daily for 48 weeks) in children <6
years (n = 25). LCI decreased (improved) significantly
more in the hypertonic saline group, as compared with con-
trols [110]. Of note, the pattern of LCI change with treat-
ment was age dependent: in a subgroup of subjects <1 year
of age, LCI was in the normal range at baseline and did not
change after treatment [110]. A recent study in older chil-
dren (mean age 14.0 years, n = 18) investigated the short
term effect of hypertonic saline inhalation [50], and found
that LCI did not change after 24 hours of treatment [50].
Responsiveness of LCI was assessed in two randomised
double-blind placebo-controlled trials in older children.
FEV1 was not systematically affected, whereas LCI im-
proved over a 1-month period after treatment with hyper-
tonic saline [111], and with dornase alfa (Pulmozyme®), an
enzymatic agent improving mucus clearance in CF [112].
A cross-sectional study assessed the effect of antibiotic
therapy on LCI abnormalities and magnet resonance imag-
ing (MRI) in clinically stable patients, aged 1 to 20 years.
LCI and MRI were able to detect an effect of antibiotic
treatment of pulmonary exacerbations [49], indicating that
these tools can provide useful endpoints for intervention
trials.
MBW indices and lung imaging
Several recent studies in children and infants compared the
association of LCI with structural airway damage or func-
tional correlates using lung imaging techniques, including
computed tomography (CT) and MRI. Studies in infants
reported poor association between LCI and bronchiectasis
as assessed with CT [47, 51], but a closer correlation was
found in preschool- and school-age children [51]. This is
not the case for spirometry indices. A strong correlation
between LCI and MRI imaging was reported in clinically
stable CF patients (age range 2–20 years) [49]. This study
further showed that LCI and MRI are able to distinguish
disease severity levels, supporting the application of these
tools for diagnostic and therapeutic monitoring. Taken to-
gether, these data support the concept of LCI as a sensitive
measure of structural airway pathology. However, LCI
cannot replace lung imaging yet as negative predictive val-
ues to exclude bronchiectasis appear too low, especially in
younger children. An overview of MBW application in CF
lung disease is given in table 2.
Wheezing
Lower respiratory tract infections, or other triggers such
as allergen exposure, leading to wheezing episodes in
preschool children, are highly prevalent. Some, but not all,
wheezers experience worsening lung function [113] and
involvement of the small airways, as assessed with MBW
and lung biopsy [114]. Functional data from MBW are
conflicting. One study measured LCI in 110 infants who
required respiratory support during the first days of life.
Measurements were performed with sedation, at approx-
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imately 5 weeks postmenstrual age. The authors found a
higher LCI in infants with less (≤3%) expiratory wheezing,
compared with infants with more (>3%) expiratory wheez-
ing [115]. These results were supported in a subsequent
study reporting a higher LCI in 40 infants without wheez-
ing compared with 41 wheezing infants [72]. These find-
ings contradict a study in preschool children, which report-
ed an increased LCI in wheezers compared with healthy
controls [114], but mean LCI differences were small (6.8
vs 6.6.) and within the normal range. Apparently, the effect
of bronchodilator inhalation on LCI is somewhat para-
doxical. LCI may increase (worsen) after inhaled salbuta-
mol in controls, but not in wheezing subjects. High vari-
ability between MBW tests at baseline and heterogeneous
response to bronchodilators questions the use of MBW
to distinguish preschool wheezers from healthy controls
[116]. To summarise, current data do not support appli-
cation of MBW measurements in infants and children to
characterise wheezing or to monitor treatment response.
Asthma
Asthma is the most common chronic respiratory disease
in children, typically characterised by eosinophilic airway
inflammation, airway hyperresponsiveness (AHR) and re-
versible airway obstruction. AHR is the ability of airways
to narrow excessively as a result of provoking stimuli.
Whereas current guidelines recommend symptom assess-
ment and spirometry for the diagnosis of asthma [117],
their value for monitoring asthma is not clear [118].
Spirometry was rather insensitive in the assessment of pe-
ripheral airways, unless severe obstruction was present
[119]. LCI in asthmatic subjects was slightly elevated com-
pared with healthy controls, but often within the normal
range, and therefore not helpful in the diagnosis of asthma
Table 2: Overview of studies in paediatric patients with cystic fibrosis using multiple-breath washout measurements.
Study description Patient
number
Age at study Study type Main findings Reference*
CF vs controls
Infants 71 3 months Cross-sectional Higher LCI and FRC in infants with CF compared with 71 controls. Hoo [102]
40 2.5–5 years Cross-sectional Higher LCI in patients with CF compared with 37 controls. Aurora [1]
48 4.09 (0.7) and
7.83 (1.3) years
Prospective Higher LCI in CF patients at preschool age compared with 45 controls.
Preschool LCI predicted abnormal LCI in CF patients at school age.
Aurora [103]
78 2.5–6 years Prospective LCI measurements in CF patients and 70 controls at 1, 3, 6 and 12
months detected lung function deterioration over time in CF patients.
Stanojevic [48]
60 7.8 (1.3) years Cross-sectional Higher LCI in CF patients compared with 60 controls. Owens [101]
43 3–18 years Cross-sectional Higher LCI and MR in CF patients compared with 28 controls. Gustafsson [100]
Preschool / school age /
adult
47 9.5–16.1 years Cross-sectional LCI was higher in CF patients compared with 50 controls. Comparison
of LCI measured with two different MBW devices revealed poor agree-
ment between different setups.
Poncin [54]
47 0.32–3.24 years Cross-sectional LCI of 25 healthy subjects was lower compared with CF patients with-
out and with bacterial infection. In CF patients, inflammatory markers
from BAL correlated with LCI.
Belessis [45]
78 4–16 years Prospective LCI was higher in CF patients compared with 53 controls. LCI strongly
correlated with Pseudomonas aeruginosa infection.
Singer [53]
108 0.1–2.5 years Prospective LCI measurements at three time points during 2 years revealed a long-
lasting increase in LCI after pulmonary infections. Haemophilus influen-
zae infections had a particularly detrimental effect on lung function.
Simpson [46]
CF with vs without bacteri-
al infection
41 8–67 years Cross-sectional LCI was higher in CF patients compared with 6 controls. A lower colony
count of aerobic/anaerobic bacteria was associated with a higher LCI in
CF patients.
O`Neill [105]
Assessment of treatment
Systematic review
of studies published
until March 2014
Overall, LCI decreased after antibiotic treatment but individual re-
sponse was heterogeneous in CF patients.
Sonneveld [106]Antibiotic treatment for pul-
monary exacerbations
26 1.8–19.9 years Prospective LCI was sensitive to detect response to antibiotic therapy for pul-
monary exacerbations.
Stahl [49]
25 1–5 years Observational Hypertonic saline twice daily for 48 weeks improved LCI. Subbarao [110]
18 7–56 years Observational Hypertonic saline 5 times over 24 hours did not improve LCI. Amin [50]
Hypertonic saline (7%)
19 10.5 (3.1) years Observational Hypertonic saline twice daily over 4 weeks improved LCI. Amin [111]
CFTR regulator ivacaftor 21 8–43 years Clinical trial Ivacaftor 150 mg twice daily for 28 days improved LCI. Davies [52]
CFTR regulators lumacaftor/
ivacaftor combined
58 6–11 years Clinical trial Lumacaftor 200 mg + ivacaftor 250 mg twice daily for 24 weeks im-
proved LCI, sweat chloride and nutritional status.
Milla [109]
Dornase alfa (Pulmozyme®) 17 6–18 years Clinical trial For weeks 2.5 ml daily Pulmozyme® inhalation improved LCI. Amin [112]
Lung imaging and MBW
Magnet resonance imaging 97 0.2–21.1 years Prospective, cross-
sectional
LCI correlated with abnormalities on MRI in infants, toddlers and chil-
dren with CF.
Stahl [49]
60 7.8 (1.3) years Cross-sectional Abnormal findings on lung CT correlated strongly with increased LCI in
CF patients.
Owens [101]
49 8.7–112.1
weeks
Cross-sectional Air trapping and bronchiectasis assessed by CT were associated with
MR, but not LCI.
Hall [47]
Computed tomography
42, 38, and
39
0–2, 3–6 and
7–16 years
Cross-sectional Agreement between LCI and bronchiectasis in preschool and school
age children, but not infants. Air trapping and LCI was only associated
in infants.
Ramsey [51]
BAL = bronchoalveolar lavage; CF = cystic fibrosis; CFTR = cystic fibrosis transmembrane conductance regulator; CT = computed tomography; LCI = lung clearance index; MR =
moment ratios; MRI = magnetic resonance imaging This table is meant to provide a current overview on studies in paediatric patients with CF and does not necessarily represent
the full body of existing literature. *At the time of publication. Age at study is given as range or mean (standard deviation).
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at the individual level [63, 120, 121]. Few studies have as-
sessed the association between MBW measures and AHR.
A study in older asthmatic subjects (age range 59–80
years) found that AHR was predicted by higher Sacin
[122], and a study in asthmatic adults (age range 18–66
years) found that AHR was associated with LCI, and that
treatment with inhaled corticosteroids decreased the LCI
[123]. In adults with severe asthma, inhaled corticosteroid
uptitration resulted in a decrease in Scond with no effect
on Sacin [124]. The study further reported that those pa-
tients with increased ventilation inhomogeneity at baseline
had the greatest improvement following inhaled corticos-
teroid dose uptitration [124]. An effect of bronchodilator
response on LCI is still poorly understood. Two studies in
children found no effect [63, 121], whereas another study
reported that the LCI was elevated in adolescents with
asthma and decreased after treatment with nebulised bron-
chodilator [125]. To summarise, MBW can be useful to ex-
plore the exact degree of airway damage and physiologi-
cal impairment in asthma, but up to now the technique is
not established for diagnosis or for monitoring treatment
response in asthma.
Chronic lung diseases of prematurity
Disruption of normal lung development because of preterm
birth results in complex structural changes in the airways,
lung parenchyma and vasculature. This may result in
smaller airway calibres and impaired alveolarisation, with
a reduced number of alveoli and enlarged airspaces [126].
The functional relevance of disrupted airway development
during infancy and thereafter is not fully understood. This
can be partly explained by the fact that the degree of air-
way obstruction was underestimated by spirometry. Recent
studies in former preterm infants used other outcomes, in-
cluding the LCI [55–57, 127–129], FRC [44, 55, 56] and
parameters specifically assessing peripheral airway dam-
age (Scond, Sacin) [57]. Results are inconsistent, probably
reflecting the heterogeneity of the disease and different
measurement techniques. Abnormal values for LCI have
been reported in preterm infants during infancy [55], and
for former preterm infants at school age [129]. Other stud-
ies reported no difference in LCI values in former preterm
infants compared with healthy subjects during early infan-
cy [56], at 1 year [44], between 9 and 11 years [130], and
between 7 and 13 years [57] of age. The last study further
investigated parameters that specifically reflect peripheral
airway ventilation. In that study, FEV1 and Scond were of-
ten abnormal at school age, whereas Sacin was compara-
ble between former preterm and healthy subjects. A func-
tionally normal alveolar compartment at school age, with
functionally abnormal central conducting airways, suggest
a disynaptic growth pattern of the lungs in former pre-
maturely born children [57]. Using MBW measurements,
studies assessed the development of lung volume. Prema-
turity was associated with a reduced FRC during early in-
fancy [55] and at 1 year of age [44].
Primary ciliary dyskinesia
Primary ciliary dyskinesia (PCD) is a rare congenital dis-
ease characterised by defective ciliary function leading to
impaired mucociliary clearance and recurrent chronic up-
per and lower airway infections [131]. The diagnosis of
PCD is challenging because of the heterogeneous nature of
the disease and poorly standardised algorithms [131]. Pa-
tients with PCD may already have reduced lung function
(FEV1, forced vital capacity [FVC]) in the preschool years
[132]. As in CF, spirometry may underestimate the full de-
gree of functional impairment in early PCD lung disease
[58, 59]. Recent studies reported marked peripheral airway
dysfunction, assessed with MBW, in almost all patients
with PCD [60, 91, 133]. Another study compared the asso-
ciation between LCI and FEV1 with structural abnormali-
ties, assessed with CT, in 38 patients. The authors reported
a higher concordance between LCI and structural abnor-
malities compared with FEV1 (83 vs 53%), suggesting that
LCI measurements may be of clinical relevance in PCD
patients [58]. Interestingly, studies using sulphur hexaflu-
oride MBW did not find this association [134]. Overall,
PCD lung disease is characterised by marked peripheral
airway dysfunction, and MBW may be a promising tool
for early detection of airway damage. Compared with CF,
MBW data in PCD are scarce. Whether MBW has utility
in the management and/or treatment of PCD still needs to
be determined in longitudinal studies.
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is charac-
terised by a variable combination of airway and parenchy-
mal abnormalities. COPD may partly develop irrespective
of tobacco smoking, and much earlier in childhood than
previously assumed [135, 136]. The hallmark of COPD is
mainly irreversible airﬂow obstruction resulting from the
narrowing of small conducting airways or loss of lung elas-
tic recoil or both. In the diagnosis of airﬂow obstruction in
COPD, simple spirometry is the main diagnostic tool, al-
though it is recognised that none of the derived parame-
ters are sensitive indicators of peripheral airway narrowing
[137, 138].
Within a prospective study of subjects who smoked
≥10-pack years, an increase in ventilation inhomogeneity
in both the conductive and acinar airways was detected
by means of normal spirometry, as indicated by increased
Scond and Sacin values. Moreover, both Scond and Sacin
were associated with FEV1/FVC values, but the former
was also associated with FEV1 and the latter with diffusion
capacity for carbon monoxide (DLCO) [139]. Similar re-
sults were reported from a cross-sectional study of 57
COPD patients with ≥15-pack years. COPD patients had
increased Sacin but not Scond values compared with
healthy controls [61], and an association between Sacin
and DLCO was also reported [89]. Taken together, these
studies suggest that MBW measurements have the poten-
tial to diagnose subclinical disease at an earlier stage, sepa-
rate airway from parenchymal abnormalities, and to further
characterise clinical features of advanced COPD. Although
good feasibility and reproducibility of washout measure-
ments in COPD patients have been shown [89], there is
still further need to validate this method for noninvasive
detection of early abnormalities or peripheral or parenchy-
mal sites [140].
Other disease groups
In addition to the application of MBW in patients with CF
and other common lung diseases, recent studies have ap-
plied this technique in less frequent lung disease, of which
some studies will be reported.
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Bronchiolitis obliterans is a small airway disease in which
chronic inflammation results in fibrotic remodelling of the
peripheral airways. It can occur, for example, after ex-
posure to toxic substances or following allogeneic
haematopoietic stem cell transplantation. Early detection
of bronchiolitis obliterans is important in order to prevent
later lung damage. One study reported abnormal washout
indices before a decrease in FEV1 was observed [141], and
measurements may even be used to detect different sever-
ity grades of bronchiolitis obliterans, as recently report-
ed [142]. In patients undergoing haematopoietic stem cell
transplantation, a study of 33 clinically stable recipients
provided some evidence that measurements of MBW were
more sensitive than spirometry to detect bronchiolitis oblit-
erans at an early stage [143].
Alpha-1-antitrypsin deficiency is a genetically inherited
disorder resulting in emphysematous lung changes. Within
a heterogeneous group of 193 patients with alpha-1-antit-
rypsin deficiency (age range 4–79 years), LCI was higher
in patients than in controls. Furthermore, LCI was found to
be abnormal in patients with normal spirometry measures,
indicating that LCI identifies lung disease related to al-
pha-1-antitrypsin deficiency earlier than spirometry, com-
parable to the chronic lung diseases discussed earlier in
this article [62].
Bronchiolitis is a common respiratory tract infection dur-
ing early childhood. A recent study included 29 infants
(mean age 3.7 months) with bronchiolitis and reported
an increased LCI compared with controls [144]. Another
prospective study enrolled infants below <1 year of age
hospitalised with bronchiolitis due to respiratory syncytial
virus infection and reported differences in FEV1, but not in
LCI, between patients and controls at the age of 18 years
[145].
MBW in ongoing clinical trials
Currently, there are more than 50 ongoing studies using
MBW indices as outcome measures listed in the North
American [146] and European [147] clinical trials reg-
istries. Most of these trials are in patients with CF or asth-
ma, but some are in less common lung diseases. We pre-
sent a selection of trials we consider interesting, although
it is not a comprehensive overview.
The first trial using LCI as primary outcome in CF patients
(aged 6–11 years) homozygous for the F508del mutation
after treatment with combined therapy of lumacaftor/iva-
caftor (Orkambi®) twice daily over 24 weeks is still on-
going [148]. The study assesses efficacy and safety of the
drug, as well as treatment effects on LCI. Two further trials
in children are investigating the treatment effect of 8 weeks
of ivacaftor. One trial is already ongoing, aiming to recruit
50 children aged 3–5 years with different CFTR mutations
to assess changes in LCI [149], and another trial will study
the efficacy of ivacaftor in subjects >6 years old, focusing
on a specific CFTR mutation [150].
One trial is being conducted in PCD patients within the
BESTCILIA (Better Experimental Screening and Treat-
ment for primary CILIAry dyskinesia) study. This is a
European multicentre, double-blind, randomised, placebo-
controlled trial with the aim to determine the efficacy of
azithromycin maintenance therapy for 6 months on respi-
ratory exacerbations in patients with PCD. This interven-
tional trial is currently ongoing and aims to recruit 125
PCD patients, aged 7–50 years old. Besides the quality-
of-life assessment, one of the main outcomes is the LCI
[151]. This trial will hopefully help elucidate whether or
not maintenance therapy with azithromycin has beneficial
effects in patients with PCD.
Several trials assess treatment response to inhaled gluco-
corticoids, betamimetics or hypertonic saline in adult [152]
and paediatric patients with asthma [153] and CF [154].
For example, in patients with CF aged 6–18 years of age,
a randomised controlled trial is assessing the short term ef-
fects (within 24 hours post-dose) of hypertonic saline in-
halation on LCI [154].
There is an observational, prospective study recruiting
children with CF and asthma, but interestingly, also chil-
dren with bronchiolitis obliterans and sickle cell anaemia
[155]. This trial will validate the MBW device for different
lung diseases in Canada, where it is not currently licensed
yet. This study may also provide insights into the applica-
tion of MBW in pulmonary complications in children with
sickle cell disease, which has not yet been investigated.
Little is currently known of the involvement of small air-
ways in patients with interstitial lung disease. One trial cur-
rently underway will perform MBW in adult patients with
different manifestations of interstitial lung disease (Weg-
ner’s Disease, idiopathic pulmonary fibrosis, sarcoidosis)
to further understand the complex pathology and heteroge-
neous presentation of these diseases [156].
Conclusion
MBW has regained interest in recent years. Reasons for
this renaissance relate to technical and physiological con-
siderations. The technique is sufficiently sensitive for the
early detection of lung function impairment often arising in
small peripheral airways. MBW provides information that
cannot currently be obtained by other lung function tests
or chest imaging. MBW is especially attractive for young
patients, as measurements require minimal cooperation.
There is mounting evidence that the LCI is useful for as-
sessing the extent and progression of lung disease, as well
as treatment response, in patients with CF. LCI is already
broadly applied in clinical care of CF patients, yet a num-
ber of unresolved questions remain. For example, there are
currently poorly defined upper limits of normal for LCI
values and its natural variability over time. Further, differ-
ent software settings and device setups may have an effect
on LCI values. Application of MBW tests in other chron-
ic lung diseases may be attractive for research, whereas
the impact on clinical management and respiratory disease
outcomes require further studies.
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